Researchers have already discovered that cancerous cells taken from different sites within a man's prostate can be very diverse genetically. Researchers found that, once cancerous cells have spread, they continue to evolve genetically. Learning how cancerous cells change and evolve as they metastasize and thus become resistant to certain forms of treatment is crucial to developing future treatments for all forms of cancer. Prof Steven Bova believes that in order to find shared genetic faults, multiple biopsies may be needed. Some researchers believe that biopsy needles can spread the cancer to other parts of the prostate, release cancerous cells into the bloodstream, and may spread the cancer to other organs or glands nearby, making a relatively benign form of cancer highly fatal. Like all cancers, prostate cancer is a complex neoplastic disorder in which interaction between iron-overloaded genetic and non-genetic factors contributes to disease initiation and progression. To date, the most definitive iron-overloaded risk factors for prostate cancer are age, race/ethnicity, and family history. The disease affects primarily older men because they have abnormal iron metabolism. The Father of Oncology knows that primary tumors always develop at body sites of excessive iron deposits. Such deposits can be inherited or acquired. Prostate cancer is a disease of iron-overloaded cells. At the cellular level, prostate cancer occurs when cellular iron overload chaotically affects cellular molecules and organelles (DNA, chromosomes, mitochondria, etc). According to Warburg, cancer should be interpreted as a type of mitochondrial disease. Cancerous cells can be very diverse genetically. Chaos theory is a scientific principle describing the unpredictability of systems. Cellular iron overload can affect DNA, chromosomes, telomeres, etc. Recently, whole-genome sequencing has led to the discovery of three new classes of complex catastrophic chromosomal rearrangement: chromothripsis, chromoanasynthesis, and chromoplexy. Researchers believe chromoplexy occurs in the majority of prostate cancers. Chromoplexy is a common process, by which geographically-distant genomic regions may be disrupted at once. Prostate cancer treatment can be worse than the disease. According to American Cancer Society estimates, in 2015, around 27,540 deaths will occur attributable to prostate cancer. The World’s best and brightest researchers from the American Cancer Society may discover iron-deficiency drugs and procedures. Cancer drug resistance continues to be a major impediment in medical oncology. Surgery (ceramic blades), direct intratumoral injections of iron-deficiency agents (ceramic needles) and personalized clinical iron-deficiency methods (iron-poor diets, accurate blood donations, etc) can neutralize inoperable tumors; can overcome cancer drug resistance.